

Director Retirement

Sydney Australia Friday, 30 June 2023: Next Science Limited (ASX: NXS) (**Next Science or Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, announces that Non-Executive Director, Bruce Hancox, is to step down from the Board with effect from 30 June 2023.

Bruce has been involved with Next Science for the past 12 years and provided sage advice and guidance through that period to assist the business to now approach a positive inflexion point on its business and financial performance.

Bruce has served on the Board for over a decade, and chaired the Audit and Risk Committee, as a 'non-independent' director. He has represented the mutual interests of all shareholders and of our major shareholder, associated interests of Mr Langley Walker.

The Board has recently overseen the appointment and commencement of Marc Zimmerman as Chief Financial Officer and the imminent commencement of I.V. Hall as new Chief Executive Officer, two immensely talented and successful executives to take Next Science into the next phase of growth and path to profitability.

In this regard, Bruce considers it now timely to retire from his role with Next Science as it transitions to new leadership under the recently appointed executive team.

Bruce stated, "Both Walker Corporation and I remain strongly committed to Next Science, as supportive shareholders, confident in its mission to heal people and save lives, and its unique and powerful technology to address the issue of biofilm-based infection in human health."

In the interim, Aileen Stockburger, who has been with Next Science since before the IPO and is an existing member of the Audit and Risk Committee, will become the Committee Chair.

Next Science will now commence a search for at least one new independent non-executive director, which may include adding a US based director.

The Board wishes to thank Bruce for his contribution over many years.

Approved and authorised for release by the Board of Directors.

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

NEXT SCIENCE®

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com